Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

Recent & Breaking News (TSXV:ARCH)

Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)

GlobeNewswire June 15, 2020

Grant of Options

GlobeNewswire June 11, 2020

Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)

GlobeNewswire June 8, 2020

Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

GlobeNewswire May 19, 2020

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

GlobeNewswire May 8, 2020

The Top Coronavirus-Related Small-Caps & Bullboards

Stockhouse Editorial April 27, 2020

Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation

GlobeNewswire April 23, 2020

Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model

GlobeNewswire March 31, 2020

ARCH BIOPARTNERS DISCLOSES NEW PATENT FILING FOR NOVEL DRUG CANDIDATES TO PREVENT LUNG INFLAMMATION

GlobeNewswire March 24, 2020

IIROC Trading Resumption - ARCH

Canada NewsWire March 17, 2020

ARCH BIOPARTNERS SAFELY COMPLETES EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL

GlobeNewswire March 17, 2020

IIROC Trading Halt - ARCH

Canada NewsWire March 16, 2020

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

GlobeNewswire March 4, 2020

Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria

GlobeNewswire February 21, 2020

Arch Biopartners Closes Convertible Note Financing

GlobeNewswire February 6, 2020

Arch Biopartners Arranges Convertible Note Financing

GlobeNewswire February 4, 2020

Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial

GlobeNewswire December 18, 2019

Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury

GlobeNewswire December 4, 2019

Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)

GlobeNewswire November 7, 2019

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage

GlobeNewswire August 22, 2019